PCI Pharma closes acquisition of LSNE to expand CDMO services

Date: 2021-12-15   Author: Pankaj Singh  Category: #news

PCI Pharma closes acquisition of LSNE to expand CDMO services

PCI Pharma Services, a leading global CDMO (contract development and manufacturing organization) has reportedly announced the closure of the acquisition of LSNE (Lyophilization Services of New England) Inc., a Bedford-headquartered premier CDMO.

Under the acquisition, LSNE will bring five FDA-approved facilities to PCI in the United States (Wisconsin, New Hampshire), and Europe (Spain) with a sixth facility expecting to receive approval in the next year. The closure of this acquisition, along with capital promises for substantial expansion of capacity, will help create a centralized hub for its clients in the Northeast region.

This acquisition is a crucial step for PCI as LSNE will broaden its services as a global CDMO and build on its proficiency in specialty manufacturing, pharmaceutical packaging, and clinical trial supply.

PCI is now capable of providing integrated small and large molecule solutions for its commercial and clinical clients which includes global manufacturing capabilities in complicated formulations, high-potency, sterile fill-finish as well as lyophilization, which is a crucial manufacturing process generally used with biologic and injectable therapies.

Notably, this is PCI’s fourth acquisition in nearly three years, strengthening the company’s dedication to include new scale and capabilities to help its clients in introducing breakthrough therapies to patients across the world.

The high-growing segment of the injectable CDMO market is outpacing the overall market of pharma outsourcing and PCI is making huge investments like this acquisition in response to the ever-growing industrial landscape.

Founded in 1997, LSNE has a spectacular history of serving global biotechnology, pharmaceutical, and medical device companies. The company is distinguished by its expertise and ability to scale lyophilization as well as its high-quality capabilities of cGMP aseptic fill-finish.

For the record, PCI is a global CDMO that provides its clients with integrated drug development, packaging, and manufacturing capabilities that increase the speed to market of the products and opportunities for commercial success.

Source credit:

https://www.businesswire.com/news/home/20211213005053/en/PCI-Pharma-Services-Announces-the-Closing-of-Its-Acquisition-of-LSNE



About Author


Pankaj Singh linkdin-boxtwitter

Pankaj Singh

Pankaj Singh Develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

Post Recommendents

Desulfurization and Denitrification Market Size | Global Industry Analysis, Segments, Top Key Players, Drivers and Trends to 2026

Author: Sachin Pashte

Global Desulfurization and Denitrification Market report focuses on the major drivers and restraints for the key players. It also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market....


Superconducting Magnetic Energy Storage (SMES) Systems Market Comprehensive Analysis, Share, Growth Forecast from 2021 to 2026

Author: Sachin Pashte

The Global Superconducting Magnetic Energy Storage (SMES) Systems Market 2021 Research Report investigates the industry thoroughly and offers a complete study on Superconducting Magnetic Energy Storage (SMES) Systems volume, market Share, market T...


Antivirus Software Market Size Current and Future Industry Trends, 2021-2026

Author: Sachin Pashte

Global Antivirus Software Report offers market size, share, overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors...